Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Laffont, Celine M.
~ 300  Ergebnisse:
Personensuche X
?
1

Comparison of intranasal naloxone and intranasal nalmefene ..:

Laffont, Celine M. ; Purohit, Prasad ; Delcamp, Nash..
Frontiers in Psychiatry.  15 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
2

An Open-Label Study to Assess Monthly Risperidone Injection..:

Walling, David P. ; Shinde, Sunita N. ; Pogoda, Janice M...
Clinical Drug Investigation.  44 (2024)  4 - p. 251-260 , 2024
Link: https://doi.org/10.1007/..
 
?
3

Examining the benefit of a higher maintenance dose of exten..:

Greenwald, Mark K. ; Wiest, Katharina L. ; Haight, Barbara R...
Harm Reduction Journal.  20 (2023)  1 - p. , 2023
Link: https://doi.org/10.1186/..
 
?
4

Effect of sustained high buprenorphine plasma concentration..:

Moss, Laurence M. ; Algera, Marijke Hyke ; Dobbins, Robert...
PLOS ONE.  17 (2022)  1 - p. e0256752 , 2022
Link: https://doi.org/10.1371/..
 
?
5

Buprenorphine exposure levels to optimize treatment outcome..:

Laffont, Celine M. ; Ngaimisi, Eliford ; Gopalakrishnan, Mathangi...
Frontiers in Pharmacology.  13 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
6

Modeling buprenorphine reduction of fentanyl-induced respir..:

Olofsen, Erik ; Algera, Marijke Hyke ; Moss, Laurence...
JCI Insight.  7 (2022)  9 - p. , 2022
Link: https://doi.org/10.1172/..
 
?
7

Evaluation of Drug‐Drug Interaction Liability for Buprenorp..:

Kharidia, Jahnavi ; Howgate, Eleanor M. ; Laffont, Celine M...
Clinical Pharmacology in Drug Development.  10 (2021)  9 - p. 1064-1074 , 2021
Link: https://doi.org/10.1002/..
 
?
8

Population Pharmacokinetics of a Monthly Buprenorphine Depo..:

Jones, Aksana K. ; Ngaimisi, Eliford ; Gopalakrishnan, Mathangi..
Clinical Pharmacokinetics.  60 (2020)  4 - p. 527-540 , 2020
Link: https://doi.org/10.1007/..
 
?
9

Tolerance to Opioid‐Induced Respiratory Depression in Chron..:

Algera, Marijke Hyke ; Olofsen, Erik ; Moss, Laurence...
Clinical Pharmacology & Therapeutics.  109 (2020)  3 - p. 637-645 , 2020
Link: https://doi.org/10.1002/..
 
?
10

A Delta-Opioid Receptor Gene Polymorphism Moderates the The..:

Kranzler, Henry R ; Lynch, Kevin G ; Crist, Richard C...
International Journal of Neuropsychopharmacology.  24 (2020)  2 - p. 89-96 , 2020
Link: https://doi.org/10.1093/..
 
?
11

Evaluation of the Effects of a Monthly Buprenorphine Depot ..:

Schmith, Virginia D. ; Curd, Laura ; Lohmer, Lauren R. L....
Clinical Pharmacology & Therapeutics.  106 (2019)  3 - p. 576-584 , 2019
Link: https://doi.org/10.1002/..
 
?
12

Pharmacokinetics of Sublingual Buprenorphine Tablets Follow..:

Dong, Ruihua ; Wang, Hongyun ; Li, Dandan...
Drugs in R&D.  19 (2019)  3 - p. 255-265 , 2019
Link: https://doi.org/10.1007/..
 
?
13

Exposure‐response analysis after subcutaneous administratio..:

Ivaturi, Vijay ; Gopalakrishnan, Mathangi ; Gobburu, Jogarao V. S....
British Journal of Clinical Pharmacology.  83 (2017)  7 - p. 1476-1498 , 2017
Link: https://doi.org/10.1111/..
 
?
14

A whole-body physiologically based pharmacokinetic (WB-PBPK..:

Sadiq, Muhammad W. ; Nielsen, Elisabet I. ; Khachman, Dalia...
Journal of Pharmacokinetics and Pharmacodynamics.  44 (2016)  2 - p. 69-79 , 2016
Link: https://doi.org/10.1007/..
 
?
15

Population Pharmacokinetic Modeling After Repeated Administ..:

Laffont, Celine M. ; Gomeni, Roberto ; Heidbreder, Christian..
The Journal of Clinical Pharmacology.  56 (2016)  7 - p. 806-815 , 2016
Link: https://doi.org/10.1002/..
 
1-15